On August 2, 2022 Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate"), a clinical-stage precision oncology company, reported that its chief executive officer, Nima Farzan, will participate in the "Bullseye – Targeted Oncology – Quanta of Targets" panel at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022 at 10:20 a.m. ET (Press release, Kinnate Biopharma, AUG 2, 2022, View Source [SID1234617272]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of the Kinnate management team will also host investor meetings during the conference.

Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Kinnate.com. A webcast replay will be made available following the event for 30 days.